公开(公告)号：US20090137782A1

公开(公告)日：2009-05-28

申请号：US10145598

申请日：2002-05-13

申请人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  V. Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice

发明人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  V. Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice

IPC分类号： C07K16/30

CPC分类号： C07K16/2863 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  A61K2300/00

摘要： The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

摘要翻译： 本发明涉及特异性结合成员，特别是抗体及其活性片段，其识别异常翻译后修饰，特别是EGFR的异常糖基化形式。 本发明的结合成员，特别是抗体及其片段在正常细胞上不与野生型基因扩增结合，并且能够以不同于 连接肽。 这种抗体的例子是其VH和VL序列如SEQ ID NO：2和4以及其嵌合抗体如ch806所示的新抗体806。

公开(公告)号：US20120183471A1

公开(公告)日：2012-07-19

申请号：US13201061

申请日：2010-02-17

申请人： Lloyd J. Old ,  Constance Old ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  Stephen Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Terrance Grant Johns ,  Con Panousis ,  Christoph Renner

发明人： Lloyd J. Old ,  Constance Old ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  Stephen Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Terrance Grant Johns ,  Con Panousis ,  Christoph Renner

IPC分类号： A61K39/395 ,  A61P35/00 ,  C12N1/19 ,  G01N33/574 ,  C12N5/10 ,  C12N1/21 ,  C07K16/30 ,  A61K51/00

CPC分类号： C07K16/40 ,  A61K31/495 ,  A61K39/39541 ,  A61K39/39558 ,  A61K47/6871 ,  A61K51/103 ,  A61K51/1045 ,  A61K51/1078 ,  A61K2039/505 ,  A61K2300/00 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/4258 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92

摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

摘要翻译： 本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

公开(公告)号：US20090220510A1

公开(公告)日：2009-09-03

申请号：US12317683

申请日：2008-12-23

申请人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Gred Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  V. Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice

发明人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Gred Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  V. Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice

IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N15/11 ,  C12P21/00 ,  G01N33/574 ,  C12N1/21 ,  C12N1/19 ,  C12N5/06 ,  C12N5/04

CPC分类号： C07K16/2863 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  A61K2300/00

摘要： The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

摘要翻译： 本发明涉及特异性结合成员，特别是抗体及其活性片段，其识别异常翻译后修饰，特别是EGFR的异常糖基化形式。 本发明的结合成员，特别是抗体及其片段在正常细胞上不与野生型基因扩增结合，并且能够以不同于 连接肽。 这种抗体的例子是其VH和VL序列如SEQ ID NO：2和4以及其嵌合抗体如ch806所示的新抗体806。

公开(公告)号：US07589180B2

公开(公告)日：2009-09-15

申请号：US10145598

申请日：2002-05-13

申请人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice

发明人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Gerd Ritter ,  Achim Jungbluth ,  Elisabeth Stockert ,  Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice

IPC分类号： C07K16/28

CPC分类号： C07K16/2863 ,  A61K39/395 ,  A61K39/39541 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  A61K2300/00

摘要： The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

公开(公告)号：US20110076232A1

公开(公告)日：2011-03-31

申请号：US12890029

申请日：2010-09-24

申请人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Achim Jungbluth ,  Elizabeth Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Gerd Ritter

发明人： Lloyd J. Old ,  Terrance Grant Johns ,  Con Panousis ,  Andrew Mark Scott ,  Christoph Renner ,  Achim Jungbluth ,  Elizabeth Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Gerd Ritter

IPC分类号： A61K51/10 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00

CPC分类号： C07K16/2863 ,  A61K39/39558 ,  A61K51/103 ,  A61K51/1045 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/30 ,  C07K16/4266 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

摘要翻译： 本发明涉及结合扩增的表皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短的特异性结合成员，特别是抗体及其片段。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

公开(公告)号：US20110313230A1

公开(公告)日：2011-12-22

申请号：US13078764

申请日：2011-04-01

申请人： Terrance Grant Johns ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elizabeth Stockert ,  Stephen Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Edward B. Reilly ,  Andrew C. Phillips ,  Jonathan A. Meulbroek ,  Fritz G. Buchanan

发明人： Terrance Grant Johns ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elizabeth Stockert ,  Stephen Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Edward B. Reilly ,  Andrew C. Phillips ,  Jonathan A. Meulbroek ,  Fritz G. Buchanan

IPC分类号： A61N5/00 ,  A61K38/19 ,  A61P35/00 ,  A61K51/00 ,  A61K38/21 ,  A61K39/395 ,  A61K38/20

CPC分类号： A61K39/3955 ,  A61K39/39541 ,  A61K39/39558 ,  A61K45/06 ,  A61K51/103 ,  A61K51/1045 ,  A61K51/1078 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/22 ,  C07K16/2863 ,  C07K16/30 ,  C07K16/4241 ,  C07K16/4258 ,  C07K16/4266 ,  C07K2299/00 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/90 ,  C07K2317/92 ,  A61K2300/00

摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

摘要翻译： 本发明涉及在过表达EGFR的肿瘤细胞上结合EGFR的特异性结合成员，特别是抗体及其片段，以及表达EGFR受体截短型de2-7EGF的肿瘤细胞。 特别地，特异性结合成员识别的表位，特别是其抗体及其片段，在异常翻译后修饰时增强或明显。 这些特异性结合成员可用于癌症的诊断和治疗。 本发明的结合成员也可用于与化学治疗剂或抗癌剂和/或与其它抗体或其片段组合的治疗中。

公开(公告)号：US20110293511A1

公开(公告)日：2011-12-01

申请号：US13078781

申请日：2011-04-01

申请人： Terrance Grant Johns ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elizabeth Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Edward B. Reilly ,  Andrew C. Phillips ,  Jonathan A. Meulbroek ,  Fritz G. Buchanan ,  Stephen Stockert

发明人： Terrance Grant Johns ,  Andrew Mark Scott ,  Gerd Ritter ,  Achim Jungbluth ,  Elizabeth Stockert ,  Vincent Peter Collins ,  Webster K. Cavenee ,  Huei-Jen Su Huang ,  Antony Wilks Burgess ,  Edouard Collins Nice ,  Anne Murray ,  George Mark ,  Lloyd J. Old ,  Edward B. Reilly ,  Andrew C. Phillips ,  Jonathan A. Meulbroek ,  Fritz G. Buchanan ,  Stephen Stockert

IPC分类号： A61K39/395 ,  A61K38/21 ,  A61K38/20 ,  A61K103/20 ,  A61K103/40 ,  A61K103/30 ,  A61K103/32 ,  A61K103/00 ,  A61P35/00

CPC分类号： C07K16/4266 ,  A61K39/39558 ,  A61K51/103 ,  A61K51/1045 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2863 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  A61K2300/00

摘要： The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

公开(公告)号：US20130345322A1

公开(公告)日：2013-12-26

申请号：US13809785

申请日：2011-07-14

申请人： Leah Jane Cosgrave ,  Bruce Tabor ,  Antony Wilks Burgess ,  Edouard Collins Nice

发明人： Leah Jane Cosgrave ,  Bruce Tabor ,  Antony Wilks Burgess ,  Edouard Collins Nice

IPC分类号： G01N33/574

CPC分类号： G01N33/57419 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N33/57488 ,  G01N2800/52

摘要： The present invention provides a method for diagnosing or detecting colorectal cancer in a subject, the method comprising determining the presence and/or level of biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1. The invention also relates to diagnostic kits comprising reagents for determining the presence and/or level of the biomarkers and methods of detecting or diagnosing colorectal cancer.

摘要翻译： 本发明提供了一种用于诊断或检测受试者的结肠直肠癌的方法，所述方法包括测定选自IL-8，IGFBP2，MAC2BP，M2PK，IL-13，DKK-3，EpCam的生物标志物的存在和/或水平， MIP1beta，TGFbeta1和TIMP-1。 本发明还涉及包含用于确定生物标志物的存在和/或水平的试剂以及检测或诊断结肠直肠癌的方法的诊断试剂盒。

公开(公告)号：US06261548B1

公开(公告)日：2001-07-17

申请号：US08839909

申请日：1997-04-21

申请人： David Paul Gearing ,  Nicholas Martin Gough ,  Douglas James Hilton ,  Julie Ann King ,  Donald Metcalf ,  Edouard Collins Nice ,  Nicos Anthony Nicola ,  Richard John Simpson ,  Tracy Ann Willson

发明人： David Paul Gearing ,  Nicholas Martin Gough ,  Douglas James Hilton ,  Julie Ann King ,  Donald Metcalf ,  Edouard Collins Nice ,  Nicos Anthony Nicola ,  Richard John Simpson ,  Tracy Ann Willson

IPC分类号： C07K1452

CPC分类号： C12N15/86 ,  A61K38/00 ,  C07K14/5415 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/23 ,  C07K2319/50 ,  C07K2319/74 ,  C07K2319/95 ,  C12N15/81 ,  C12N2740/13043 ,  C12P21/02 ,  C12P21/06

摘要： The present invention provides isolated DNA molecules encoding human and murine LIF and methods of producing LIF by the expression of the isolated DNA and suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.

摘要翻译： 本发明提供编码人和鼠LIF的分离的DNA分子和通过分离的DNA和合适的宿主细胞的表达产生LIF的方法。 本发明还提供人和鼠LIF多肽，含有LIF的药物组合物及其使用方法。

公开(公告)号：US20100261162A1

公开(公告)日：2010-10-14

申请号：US11644197

申请日：2006-12-22

申请人： Edouard Collins Nice ,  Julie Ann Rothacker

发明人： Edouard Collins Nice ,  Julie Ann Rothacker

IPC分类号： C12Q1/68

CPC分类号： C12Q1/68 ,  C12Q1/6844 ,  C12Q1/6886 ,  C12Q2565/537 ,  C12Q2533/101 ,  C12Q2521/113

摘要： The present invention relates generally to the field of diagnostic and prognostic assays such as diagnostic assays for conditions associated with telomerase activity. More particularly, the present invention provides an assay for measuring telomerase activity as an indicator of cancer, an inflammatory disorder and/or a condition involving embryogenesis and/or requiring stem cell proliferation and agents and kits useful for same. Automated and partially automated assays permitting high throughput screening also form part of the present invention. The subject invention further contemplates methods of treatment using agents identified by the subject assay or where treatment protocols are monitored by the assay.

摘要翻译： 本发明一般涉及诊断和预后测定领域，例如与端粒酶活性相关的病症的诊断测定。 更具体地，本发明提供了测定端粒酶活性作为癌症，炎症性疾病和/或涉及胚胎发生和/或需要干细胞增殖的病症的指标的测定法，以及对其有用的试剂和试剂盒。 允许高通量筛选的自动化和部分自动化测定也构成本发明的一部分。 本发明进一步考虑使用通过本发明测定法鉴定的试剂的治疗方法或通过测定法监测治疗方案。